MIF: A new cytokine link between rheumatoid arthritis and atherosclerosis

Nature Reviews Drug Discovery

Volumn 5, Issue 5, 2006, Pages 399-411

  Morand, Eric F ^a   Leech, Michelle ^a   Bernhagen, Jürgen ^b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 FLUORO PARA HYDROXYCINNAMATE; 3 (4 HYDROXYPHENYL) 4,5 DIHYDRO 5 ISOXAZOLE ACETIC ACID METHYL ESTER; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E; AVP 13536; AVP 13546; AVP 13748; C REACTIVE PROTEIN; COR 100140; CYCLOOXYGENASE 2; CYTOKINE; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; ISO 1; LEVO TRYPTOPHAN SCHIFF BASE; MACROPHAGE MIGRATION INHIBITION FACTOR; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; SMALL INTERFERING RNA; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ATHEROMA; ATHEROSCLEROSIS; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; DYSLIPIDEMIA; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; GENE TARGETING; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; LEUKOCYTE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ANALYSIS;

ANIMALS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; GLUCOCORTICOIDS; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS;

EID: 33745190762     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2029     Document Type: Review

References (130)

1. Charo, I. F. & Ransohoff, R. M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610-621 (2006).
2. David, J. R. Delayed hypersensitivity in vitro: Its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl Acad. Sci. USA 56, 72-77 (1966).
3. Sorg, C. Characterization of murine macrophage migration inhibitory activities (MIF) released by concanavalin A stimulated thymus or spleen cells. Mol. Immunol. 17, 565-569 (1980).
4. Smolen, J. S. & Steiner, G. Therapeutic strategies for rheumatoid arthritis. Nature Rev. Drug Discov. 2, 473-488 (2003).
5. Mikulowska, A., Metz, C. N., Bucala, R. & Holmdahl, R. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J. Immunol. 158, 5514-5517 (1997).
6. Leech, M. et al. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum. 41, 910-917 (1998).
7. Leech, M., Metz, C., Bucala, R. & Morand, E. F. Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum. 43, 827-833 (2000).
8. Santos, L. L., Hall, P., Metz, C. N., Bucala, R. & Morand, E. F. Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: Interaction with glucocorticoids. Clin. Exp. Immunol. 123, 309-314 (2001).
9. Bernhagen, J. et al. An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J. Exp. Med. 183, 277-282 (1996).
10. Onodera, S. et al. Macrophage migration inhibitory factor up-regulates the expression of interleukin-8 messenger RNA in synovial fibroblasts of rheumatoid arthritis patients: Common transcriptional regulatory mechanism between interleukin-8 and interleukin-1β. Arthritis Rheum. 50, 1437-1447 (2004).
11. Ichiyama, H. et al. Inhibition of joint inflammation and destruction induced by anti-type II collagen antibody/lipopolysaccharide (LPS)-induced arthritis in mice due to deletion of macrophage migration inhibitory factor (MIF). Cytokine 26, 187-194 (2004).
12. Leech, M. et al. Regulation of p53 by macrophage migration inhibitory factor (MIF) in inflammatory arthritis. Arthritis Rheum. 48, 1881-1889 (2003).
13. Gregory, J. L. et al. Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice. Arthritis Rheum. 50, 3023-3034 (2004).
14. Leech, M. et al. Macrophage migration inhibitory factor in rheumatoid arthritis: Evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum. 42, 1601-1608 (1999).
15. Onodera, S. et al. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine 11, 163-167 (1999).
16. Morand, E. F. et al. Macrophage migration inhibitory factor in rheumatoid arthritis: Clinical correlations. Rheumatology (Oxford) 41, 558-562 (2002).
17. Sampey, A. V., Hall, P. H., Mitchell, R. A., Metz, C. N. & Morand, E. F. Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor. Arthritis Rheum. 44, 1273-1280 (2001).
18. Santos, L., Lacey, D. C., Yang, Y., Leech, M. & Morand, E. F. Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor (MIF). J. Rheumatol. 31, 1038-1043 (2004).
19. Onodera, S. et al. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J. Biol. Chem. 275, 444-450 (2000).
20. Onodera, S. et al. Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular signaling pathways. J. Biol. Chem. 277, 7865-7874 (2002).
21. Lacey, D. et al. Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. Arthritis Rheum. 48, 103-109 (2003).
22. Mitchell, R. A. et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl Acad. Sci. USA 99, 345-350 (2002).
23. Baugh, J. A. et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun. 3, 170-176 (2002).
24. Radstake, T. R. et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum. 52, 3020-3029 (2005).
25. Donn, R. et al. A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum. 50, 1604-1610 (2004).
26. Donn, R. P. et al. Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J. Invest. Dermatol. 123, 484-487 (2004).
27. Amoli, M. M. et al. Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. J. Rheumatol. 29, 1671-1673 (2002).
28. Nohara, H. et al. Association of the -173 G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J. Gastroenterol. 39, 242-246 (2004).
29. Libby, P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002).
30. Lusis, A. J. Atherosclerosis. Nature 407, 233-241 (2000).
31. Ross, R. The pathogenesis of atherosclerosis: Perspective for the 1990s. Nature 362, 801-809 (1993).
32. Ross, R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
33. Nissen, S. E. et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352, 29-38 (2005).
34. Hansson, G. K., Libby, P., Schonbeck, U. & Yan, Z. O. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91, 281-291 (2002).
35. Schober, A. & Weber, C. Mechanisms of monocyte recruitment in vascular repair after injury. Antioxid. Redox Signal. 7, 1249-1257 (2005).
36. Burger-Kentischer, A. et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 105, 1561-1566 (2002).
37. Burger-Kentischer, A. et al. Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis 184, 28-38 (2006).
38. Lin, S. G. et al. De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ. Res. 87, 1202-1208 (2000).
39. Pan, J. H. et al. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 109, 3149-3153 (2004).
40. Ip, J. H. et al. Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation. J. Am. Coll. Cardiol. 15, 1667-1687 (1990).
41. Shah, P. K. Inflammation, neointimal hyperplasia, and restenosis: As the leukocytes roll, the arteries thicken. Circulation 107, 2175-2177 (2003).
42. Chen, Z. et al. Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler. Thromb. Vasc. Biol. 24, 709-714 (2004).
43. Schober, A. et al. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 109, 380-385 (2004).
44. Pan, J. H. et al. Macrophage migration inhibitory factor is associated with aneurysmal expansion. J. Vasc. Surg. 37, 628-635 (2003).
45. Atsumi, T., Nishihira, J., Makita, Z. & Koike, T. Enhancement of oxidised low-density lipoprotein uptake by macrophages in response to macrophage migration inhibitory factor. Cytokine 12, 1553-1556 (2000).
46. Verschuren, L. et al. Up-regulation and coexpression of MIF and matrix metalloproteinases in human abdominal aortic aneurysms. Antioxid. Redox Signal. 7, 1195-1202 (2005).
47. Kong, Y. Z. et al. Macrophage migration inhibitory factor induces MMP-9 expression: Implications for destabilization of human atherosclerotic plaques. Atherosclerosis 178, 207-215 (2005).
48. Kong, Y. Z. et al. Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques. Cardiovasc. Res. 65, 272-282 (2005).
49. Kusuhara, M., Chait, A., Cader, A. & Berk, B. C. Oxidized LDL stimulates mitogen-activated protein kinases in smooth muscle cells and macrophages. Arterioscler. Thromb. Vasc. Biol. 17, 141-148 (1997).
50. Hudson, J. D. et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190, 1375-1382 (1999).
51. Mitchell, R. A. et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl Acad. Sci. USA 99, 345-350 (2002).
52. Simelyte, E. et al. Regulation of arthritis by p53: Critical role of adaptive immunity. Arthritis Rheum. 52, 1876-1884 (2005).
53. Mercer, J., Figg, N., Stoneman, V., Braganza, D. & Bennett, M. R. Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice. Circ. Res. 96, 667-674 (2005).
54. Asanuma, Y. et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2407-2415 (2003).
55. Roman, M. J. et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2399-2406 (2003).
56. Van Doornum, S., McColl, G. & Wicks, I. P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 46, 862-873 (2002).
57. del Rincon, I. D., Williams, K., Stern, M. P., Freeman, G. L. & Escalante, A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 44, 2737-2745 (2001).
58. Foote, A. et al. Macrophage migration inhibitory factor in systemic lupus erythematosus. J. Rheumatol. 31, 268-273 (2004).
59. Walsh, L. J., Wong, C. A., Pringle, M. & Tattersfield, A. E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: A cross sectional study. Brit. Med. J. 313, 344-346 (1996).
60. Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353, 1114-1123 (2005).
61. Yang, Y. et al. Modulation of inflammation and response to dexamethasone by annexin-1 in antigen-induced arthritis. Arthritis Rheum. 50, 976-984 (2004).
62. Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A. & Karin, M. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis. Science 270, 286-290 (1995).
63. Ito, K. et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression. J. Exp. Med. 203, 7-13 (2006).
64. Choi, J. H. et al. Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25, 2404-2409 (2005).
65. Wiley, R. E. et al. Transient corticosteroid treatment permanently amplifies the Th2 response in a murine model of asthma. J. Immunol. 172, 4995-5005 (2004).
66. Calandra, T. et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377, 68-71 (1995).
67. Roger, T., Chanson, A. L., Knaup-Reymond, M. & Calandra, T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur. J. Immunol. 35, 3405-3413 (2005).
68. Aeberli, D. et al. Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett. 580, 974-981 (2006).
69. Sapolsky, R. M., Romero, L. M. & Munck, A. U. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 21, 55-89 (2000).
70. Munck, A., Guyre, P. M. & Holbrook, N. J. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr. Rev. 5, 25-44 (1984).
71. Dhabhar, F. S. & McEwen, B. S. Enhancing versus suppressive effects of stress hormones on skin immune function. Proc. Natl Acad. Sci. USA 96, 1059-1064 (1999).
72. Galon, J. et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 16, 61-71 (2002).
73. Barnes, P. J. Anti-inflammatory actions of glucocorticoids - molecular mechanisms. Clin. Sci. 94, 557-572 (1998).
74. Faggiano, A. et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J. Clin. Endocrinol. Metab. 88, 2527-2533 (2003).
75. Colao, A. et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J. Clin. Endocrinol. Metab. 84, 2664-2672 (1999).
76. Pivonello, R., Faggiano, A., Lombardi, G. & Colao, A. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol. Metab. Clin. North Am. 34, 327-339, viii (2005).
77. Kirilov, G. et al. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome. Eur. J. Endocrinol. 149, 549-553 (2003).
78. Hurwitz Eller, N., Netterstrom, B. & Hansen, A. M. Cortisol in urine and saliva: Relations to the intima media thickness, IMT. Atherosclerosis 159, 175-185 (2001).
79. Maddali, K. K., Korzick, D. H., Turk, J. R. & Bowles, D. K. Isoform-specific modulation of coronary artery PKC by glucocorticoids. Vascul. Pharmacol. 42, 153-162 (2005).
80. Hermanowski-Vosatka, A. et al. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 202, 517-527 (2005).
81. Feldmann, M. et al. Future prospects for anti-cytokine treatment. Ann. Rheum. Dis. 59 (Suppl. 1), 119-122 (2000).
82. Taylor, P. C., Williams, R. O. & Feldmann, M. Tumour necrosis factor α as a therapeutic target for immune-mediated inflammatory diseases. Curr. Opin. Biotechnol. 15, 557-563 (2004).
83. Thomson, A. W. The Cytokine Handbook (Academic, New York, 2003).
84. Pugsley, M. K. Etanercept. Immunex. Curr. Opin. Investig. Drugs 2, 1725-1731 (2001).
85. Toussirot, E. & Wendling, D. The use of TNF-α blocking agents in rheumatoid arthritis: An overview. Expert Opin. Pharmacother. 5, 581-594 (2004).
86. Braddock, M. & Quinn, A. Targeting IL-1 in inflammatory disease: New opportunities for therapeutic intervention. Nature Rev. Drug Discov. 3, 330-339 (2004).
87. Calandra, T. et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nature Med. 6, 164-170 (2000).
88. Bernhagen, J. et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365, 756-759 (1993).
89. Sakai, Y. et al. Macrophage migration inhibitory factor is a critical mediator of severe acute pancreatitis. Gastroenterology 124, 725-736 (2003).
90. Leng, L. et al. MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197, 1467-1476 (2003).
91. Meyer-Siegler, K. L., Leifheit, E. C. & Vera, P. L. Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer 4, 34 (2004).
92. Palladino, M. A., Bahjat, F. R., Theodorakis, E. A. & Moldawer, L. L Anti-TNF-α therapies: The next generation. Nature Rev. Drug Discov. 2, 736-746 (2003).
93. Thiele, M. & Bernhagen, J. Link between macrophage migration inhibitory factor and cellular redox regulation. Antioxid. Redox Signal. 7, 1234-1248 (2005).
94. Kleemann, R. et al. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as a thiol-protein oxidoreductase. J. Mol. Biol. 280, 85-102 (1998).
95. Rosengren, E. et al. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol. Med. 2, 143-149 (1996).
96. Rosengren, E. et al. The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. FEBS Lett 417, 85-88 (1997).
97. Swope, M., Sun, H.-W., Blake, P. R. & Lolis, E. Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor. EMBO J. 1, 3534-3541 (1998).
98. Bendrat, K. et al. Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry 36, 15356-15362 (1997).
99. Hermanowski-Vosatka, A. et al. Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration. Biochemistry 38, 12841-12849 (1999).
100. Kleemann, R., Kapurniotu, A., Mischke, R., Held, J. & Bernhagen, J. Characterization of catalytic centre mutants of macrophage migration inhibitory factor (MIF) and comparison to Cys81 Ser MIF. Eur. J. Biochem. 261, 753-766 (1999).
101. Kleemann, R. et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408, 211-216 (2000).
102. Stamps, S. L., Fitzgerald, M. C. & Whitman, C. P. Characterization of the role of the amino-terminal proline in the enzymatic activity catalyzed by macrophage migration inhibitory factor. Biochemistry 37, 10195-10202 (1998).
103. Lubetsky, J. B., Swope, M., Dealwis, C., Blake, P. & Lolis, E. Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity. Biochemistry 38, 7346-7354 (1999).
104. Philo, J. S., Yang, T. H. & LaBarre, M. Re-examining the oligomerization state of macrophage migration inhibitory factor (MIF) in solution. Biophys. Chem. 108, 77-87 (2004).
105. Jasanoff, A., Wagner, G. & Wiley, D. C. Structure of a trimeric domain of the MHC class II-associated chaperonin and targeting protein Ii. EMBO J. 17, 6812-6818 (1998).
106. Taylor, A. B. et al. Crystal structure of macrophage migration inhibitory factor complexed with (E)-2-fluoro-p-hydroxycinnamate at 1.8 Å resolution: Implications for enzymatic catalysis and inhibition. Biochemistry 38, 7444-7452 (1999).
107. Orita, M., Yamamoto, S., Katayama, N. & Fujita, S. Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors. Curr. Pharm. Des. 8, 1297-1317 (2002).
108. Morand, E. F., Leech, M. & Iskander, M. Therapeutic opportunities for antagonism of macrophage migration inhibitory factor. Expert Opin. Ther. Patents 8, 1189-1212 (2003).
109. Dios, A. et al. Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J. Med. Chem. 45, 2410-2416 (2002).
110. Lubetsky, J. B. et al. The tautomerase activity of MIF is a potential target for discovery of novel anti-inflammatory agents. J. Biol. Chem. 277, 24976-24982 (2002).
111. Senter, P. D. et al. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc. Natl Acad. Sci. USA 99, 144-149 (2002).
112. Zhuang, S. et al. Some insights into the stereochemistry of inhibition of macrophage migration inhibitory factor with 2-fluoro-p-hydroxycinnamate and its analogues from molecular dynamics simulations. J. Med. Chem. 48, 7208-7214 (2005).
113. Nguyen, M. T. et al. A sixteen residue peptide fragment of macrophage migration inhibitory factor, MIF(50-65), exhibits redox activity and has MIF-like biological functions. J. Biol. Chem. 278, 33654-33671 (2003).
114. Petrenko, O., Fingerle-Rowson, G., Peng, T., Mitchell, R. A. & Metz, C. N. MIF-deficiency is associated with altered cell growth and reduced susceptibility to Ras-mediated transformation. J. Biol. Chem. 278, 11078-11085 (2003).
115. Petrenko, O. & Moll, U. M. Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol. Cell 17, 225-236 (2005).
116. Nguyen, M. T. et al. The cytokine macrophage migration inhibitory factor reduces pro-oxidative stress-induced apoptosis. J. Immunol. 170, 3337-3347 (2003).
117. Chamovitz, D. A. & Segal, D. JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep. 2, 96-101 (2001).
118. Wadgaonkar, R. et al. Intracellular interaction of myosin light chain kinase with macrophage migration inhibition factor (MIF) in endothelium. J. Cell. Biochem. 95, 849-858 (2005).
119. Swant, J. D., Rendon, B. E., Symons, M. & Mitchell, R. A. Rho GTPase-dependent signaling is required for MIF-mediated expression of cyclin D1. J. Biol. Chem. 280, 23066-23072 (2005).
120. Jung, H., Kim, T., Chae, H. Z., Kim, K. T. & Ha, H. Regulation of macrophage migration inhibitory factor and thiol-specific antioxidant protein PAG by direct interaction. J. Biol. Chem. 276, 15504-15510 (2001).
121. Lue, H. et al. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal. 18, 688-703 (2006).
122. Kleemann, R. et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408, 211-216 (2000).
123. Roger, T., David, J., Glauser, M. & Calandra, T. MIF regulates innate immune responses through modulation of Toll-like receptor-4. Nature 414, 920-924 (2001).
124. Al-Abed, Y. et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J. Biol. Chem. 280, 36541-36544 (2005).
125. Cvetkovic, I. et al. Critical role of macrophage migration inhibitory factor (MIF) activity in experimental autoimmune diabetes. Endocrinology 146, 2942-2951 (2005).
126. Bacher, M. et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl Acad. Sci. USA 93, 7849-7854 (1996).
127. Calandra, T., Bernhagen, J., Mitchell, R. A. & Bucala, R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 179, 1895-1902 (1994).
128. Mitchell, R. A., Metz, C. N., Peng, T. & Bucala, R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J. Biol. Chem. 274, 18100-18106 (1999).
129. Chesney, J. et al. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol. Med. 5, 181-191 (1999).
130. Lacey, D. C. et al. Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor (MIF). Arthritis Rheum. 48, 103-109 (2003).